Medtronic ($MDT) has launched its latest pacemaker in Europe, picking up CE mark clearance for Viva CRT-P, a device it touts as improving patient response rates. The implant, a cardiac resynchronization therapy pacemaker, is outfitted with Medtronic's AdaptivCRT software, an algorithm-based technology designed to automatically adjust pacing to patients' specific heart function. In clinical trials, the software demonstrated a 21% reduction in heart failure hospitalization and a 46% decline in risk of atrial fibrillation, according to Medtronic. More